glp 1 and parkinson's A new Science Perspective highlights the growing body of evidence that hints at the potential of GLP-1–based medications in treating conditions other than diabetes obesity, including cardiovascular disease and neurodegenerative disorders PDF] Novel dual GLP-1/GIP receptor

These studies contribute to a broader understanding of growth factor signaling and molecular regulation under controlled experimental conditions

Beginner's tip: change from beef

From the copper peptide for skin research that has generated multiple positive human clinical trials, to emerging data on GHK-Cu injection protocols for systemic anti-aging applications, the compound represents a convergence of cosmeceutical, regenerative, and longevity science that is increasingly difficult to ignore

Semaglutide was originally intended for use in diabetic patients through subcutaneous injections

GHK-Cu helps to reverse this process by upregulating the expression of genes involved in collagen and elastin synthesis, effectively rebuilding the skin's extracellular matrix